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In a double blind randomised controlled trial, 30 infants
with chronic lung disease received fluticasone propionate
or placebo for one year. There were no significant
differences between treatment groups in the incidence of
any day or night time symptoms or any other outcome
measures.
Chronic lung disease of prematurity (CLD) is associatedwith significant respiratory morbidity in the early yearsof life.1 2 Systemic corticosteroids reduce the duration of
respiratory support in infants at risk of developing CLD.3
Inhaled corticosteroids reduce symptoms in wheezing
infants.4 No randomised controlled studies have assessed the
efficacy of inhaled corticosteroids as prophylactic therapy in
CLD. We report the results of a randomised double blind pla-
cebo controlled trial of inhaled fluticasone propionate in
infants with CLD, which aimed to determine whether the
regular use of an inhaled corticosteroid reduces respiratory
morbidity.
Infants studied required supplementary oxygen at 36 post-
menstrual weeks. They were excluded if they were ventilated
or receiving systemic corticosteroids at this time. Local
research ethics approval was granted and written informed
parental consent obtained. Infants were randomised to receive
250 µg twice daily of inhaled fluticasone propionate or placebo
viametered dose inhaler (with spacer and facemask) for a one
year study period. Treatment allocation was double blinded.
Primary outcome was the incidence of reported symptom free
days. Secondary outcomes included symptom frequency
(assessed using a symptom diary), growth parameters, and
hospital admissions. It was estimated that placebo treated
infants may experience symptoms on 50% of days. Sample size
calculation, looking for a 20% reduction in symptom
frequency in fluticasone treated infants (80% power, 95% con-
fidence) revealed that 63 infants were required in each treat-
ment arm. After two years recruitment, it became evident that
the original sample size would not be achieved in a reasonable
time. A decision was taken to stop the trial but to report avail-
able data for use in designing future studies or systematic
reviews.
Thirty infants were randomised to the study; 15 received
fluticasone (table 1). Two infants in the fluticasone treated
group and three in the placebo arm withdrew from the trial
without completing diaries. Three infants had no symptom
diaries complete despite continuing treatment, one from the
fluticasone arm and two from the placebo arm of the trial.
There were no significant differences between treatment
groups in the incidence of any day or night time symptoms
(table 2). The median (interquartile range) duration of
continuous oxygen therapy was 181 days (133–301) for fluti-
casone and 119 days (56–280) for placebo treated infants
(p = 0.4), while the median duration of inhaler usage was 350
days (113–373) and 242 days (97–301) respectively (p = 0.4).
Table 1 Patient characteristics
Fluticasone (n=15) Placebo (n=15)
Male 8 (53%) 9 (60%)
Gestation (wk) 27 (25 to 28) 28 (27 to 30)
Birth weight (g) 864 (755 to 1058) 1120 (820 to 1430)
Z score 0.17 (−0.43 to 0.84) −0.21 (−0.45 to 0.57)
Birth OFC (cm) 25.2 (23.8 to 30) 26.2 (23.5 to 28.6)
Z score 0.24 (−1.18 to 1.17) 0.06 (−0.95 to 0.50)
Respiratory support
Total ventilated days 17 (13 to 34) 15 (7 to 25)
Maximum PIP (cmH2O) 25 (20 to 28) 26 (20 to 32)
Maximum (FiO2 (%) 71 (55 to 100) 100 (70 to 100)
Characteristics at recruitment
Age (corrected weeks) 39 (38 to 43) 40 (37 to 42)
Weight (g) 2458 (2100 to 2870) 2390 (2042 to 2637)
Z score −1.57 (−3.05 to −1.01) −1.76 (−2.70 to −1.27)
OFC (cm) 33.6 (32.2 to 35.5) 33.5 (32.4 to 34.0)
Z score −0.55 (−2.46 to 0.78) −0.77 (−1.56 to 0.29)
Supplemental oxygen (l/min) 0.25 (0.1 to 0.4) 0.15 (0.05 to 0.3)
Results expressed as median (interquartile range).
OFC, occipitofrontal circumference; PIP, peak inspiratory pressure; FiO2, fractional inspired oxygen.
F62
www.archdischild.com
There was no significant difference between treatment groups
with respect to weight gain expressed as Z score or increase in
hospital admissions for respiratory illness, number of courses
of oral corticosteroids, or the use of bronchodilator therapy
during the study period.
Fluticasone is a potent inhaled corticosteroid5 and the lack
of a major clinical effect might be a result of poor treatment
adherence, an insensitive outcome measure, or a type II error.
Double blinding of participants optimised the chance of
detecting a significant treatment effect. Stratification by
centre compensated for potential variation in management
regimes. Efficacy of an inhaled prophylactic therapy depends
on adequate and regular administration. Parents were trained
in the inhaler technique and regularly monitored. Being a
pragmatic trial, no objective measure of treatment adherence
(for example, weighing of canisters) was adopted. Use of
symptom diaries, though easy to complete and regularly
supervised, relies on parental motivation and interpretation of
symptoms. The eight infants either withdrawing or not com-
pleting symptom diaries were excluded from analyses.No data
were available for the primary outcomemeasure and therefore
they could not be included in an intention to treat analysis.
This study provides useful data regarding respiratory symp-
tomatology in placebo treated infants with CLD. Approxi-
mately 19% of infants with CLD treated with placebo had
short episodes of cough or wheeze during the day and 20%
had similar episodes sufficient to wake them at least once at
night. These are substantially lower frequencies than our esti-
mated values for sample size calculation (50%) and indicate
that a much larger sample size would be need to detect impor-
tant differences in symptom frequency in this population.
In conclusion, this is a small, negative outcome study that
does not encourage clinicians to start inhaled corticosteroids
prophylactically in infants with CLD. A larger clinical trial of
treatment in symptomatic children with CLD would be the
next appropriate step.
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Table 2 Incidence of respiratory symptoms reported in diaries
Fluticasone (n=12) Placebo (n=10) p value
Data days per patient 296 (66 to 358) 220 (85 to 313) 0.42
Incidence of day time symptoms (% days)
None 67 (50 to 85) 81 (48 to 97) 0.50
One or more episodes 33 (15 to 50) 19 (3 to 52) 0.50
Two or more episodes 11 (3 to 25) 7 (0 to 20) 0.37
Reliever used during day 1 (0 to 12) 3 (0 to 12) 0.72
Incidence of night time symptoms (% nights)
None 76 (58 to 94) 80 (44 to 95) 0.87
Woke once or more 24 (6 to 42) 20 (5 to 56) 0.87
Woke twice or more 6 (4 to 20) 7 (9 to 37) 0.67
Reliever used at night 4 (0 to 26) 1 (0 to 6) 0.50
Results expressed as median (interquartile range).
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